Genitourinary Cancers | Specialty

Tyrosine Kinase Inhibitors Used Alone or in Combination to Treat RCC

July 29th 2019

Factors Influencing Choice of Sequential Therapy in RCC

July 29th 2019

Patient-Reported Outcomes for RCC Treatment Therapies

July 29th 2019

Role of Risk Stratification in Treatment Planning for mRCC

July 29th 2019

NCCN Guideline Changes for First- & Beyond-First-Line RCC Therapy

July 29th 2019

Cytoreductive Nephrectomy in Metastatic RCC

July 29th 2019

CheckMate 214 Trial for Newly Diagnosed Metastatic RCC

July 29th 2019

Additive and Overlapping Adverse Effects of RCC Therapy

July 29th 2019

Pembrolizumab Plus Axitinib for Advanced RCC

July 29th 2019

EU Panel Backs Pembrolizumab Plus Axitinib for Frontline RCC

July 29th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.

Erdafitinib Urothelial Carcinoma Data Update Shows Strong Response

July 25th 2019

Erdafitinib induced an objective response rate of 40% in previously treated patients with locally advanced or metastatic urothelial carcinoma, according to findings from the pivotal phase II BLC2001 trial published in the New England Journal of Medicine.

Dr. Pal on the Design of the SWOG 1500 Trial in Papillary RCC

July 23rd 2019

Sumanta Kumar Pal, MD, an associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program, and medical oncologist at City of Hope, discusses the design of the phase II SWOG 1500 trial (NCT02761057) in locally advanced or metastatic papillary renal cell carcinoma (RCC).

Immunotherapy/TKI Combos Continue to Advance RCC Paradigm

July 19th 2019

Claud M. Grigg Jr, MD, highlights data from pivotal trials with combinations in both clear cell and non-clear cell renal cell carcinoma, as well as challenges with identifying biomarkers for immunotherapy.

Investigators Seek to Boost Surgical Cures in RCC With Immune Priming

July 18th 2019

In the phase III PROSPER trial, investigators will attempt a novel approach in localized renal cell carcinoma: priming the immune system prior to nephrectomy with neoadjuvant nivolumab and continuing with adjuvant blockade. The study will be the first to combine neoadjuvant and adjuvant immunotherapy with standard of care nephrectomy.

FDA Approval Sought for Enfortumab Vedotin for Urothelial Cancer

July 16th 2019

A biologics license application has been submitted to the FDA for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

Dr. Choueiri on the Next Generation of Trials in RCC

July 16th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses the next generation of trials in renal cell carcinoma (RCC).

Immunotherapy Research Continues to Emerge in Urothelial Cancer

July 12th 2019

Robert Dreicer, MD, highlights the current state of immunotherapy in urothelial cancer and ongoing research poised to offer more information on how to broaden its effects.

Dr. Choueiri on Checkpoint Inhibitors to Treat Sarcomatoid Carcinoma

July 11th 2019

Toni Choueiri, MD, discusses the use of checkpoint inhibitors to treat patients with sarcomatoid carcinoma.

Dr. Shuch on the Impact of the SURTIME Trial in Advanced RCC

July 11th 2019

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses the impact of the phase III SURTIME study in advanced renal cell carcinoma (RCC).

Dr. Choueiri on Frontline Combination Therapies in mRCC

July 10th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses the frontline combination therapies that are available for the treatment of patients with metastatic renal cell carcinoma (mRCC).